SCHEDULE 13G/A: Morgan Stanley Reduces Stake in Sage Therapeutics Below 5% Threshold

Sentiment:

Beneficial Ownership Amendment 6 March 2025 9:28 PM

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed an amended Schedule 13G indicating they are no longer beneficial owners of more than five percent of Sage Therapeutics, Inc.'s common stock.

Worse than expectedMorgan Stanley, a major institutional investor, has reduced its beneficial ownership in Sage Therapeutics, Inc. from above 5% to 1.6% (Morgan Stanley) and 0.3% (Morgan Stanley & Co. LLC), which can be perceived as a negative signal by the market.

Summary

Morgan Stanley and its wholly-owned subsidiary, Morgan Stanley & Co. LLC, have filed an Amendment No. 1 to Schedule 13G for Sage Therapeutics, Inc.
The filing indicates that Morgan Stanley has ceased to be the beneficial owner of more than five percent of Sage Therapeutics' common stock as of February 28, 2025.
Morgan Stanley now beneficially owns an aggregate of 1,012,337 shares, representing 1.6% of the class of securities.
Morgan Stanley & Co. LLC beneficially owns an aggregate of 172,743 shares, representing 0.3% of the class of securities.
The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Sage Therapeutics.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a major institutional investor has reduced its stake below a significant ownership threshold, which can be interpreted as a lack of conviction or portfolio rebalancing away from the issuer.

Positives

Negatives

Morgan Stanley, a significant institutional investor, has reduced its beneficial ownership in Sage Therapeutics, Inc. to below the 5% threshold, indicating a decreased stake in the company.

Risks

Future Outlook

This document does not contain any forward-looking statements or guidance regarding Sage Therapeutics, Inc.'s future performance or outlook.

Industry Context

This filing is a routine disclosure of a change in institutional ownership, reflecting a large financial institution's adjustment to its portfolio. It does not provide specific insights into broader industry trends or competitive dynamics beyond the fact that Morgan Stanley is a significant player in the financial markets.

Related Party Transactions

Morgan Stanley & Co. LLC is a wholly-owned subsidiary of Morgan Stanley, and its holdings are reported as part of Morgan Stanley's beneficial ownership.

Stakeholder Impact

Shareholders: The reduction in a significant institutional stake may influence investor sentiment and potentially the stock price, as it indicates a large investor has reduced their exposure to the company.

Key Dates

Date	Description
02/28/2025	Date of event which required the filing of this statement (Morgan Stanley ceased to be beneficial owner of more than five percent).
03/06/2025	Date of filing of the Schedule 13G Amendment No. 1.

Keywords

Sage Therapeutics, Morgan Stanley, Schedule 13G, Beneficial Ownership, Institutional Ownership, Common Stock, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.